Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ochromycinone, also widely known by the code name STA-21, is a natural angucyclinone antibiotic and a small molecule inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway. Originally isolated from various *Streptomyces* species, such as *Streptomyces ochraceus*, it possesses a characteristic tetracyclic benz[a]anthracene skeleton. Ochromycinone functions by specifically binding to the SH2 domain of STAT3, which prevents its dimerization and subsequent DNA binding. This inhibition disrupts the expression of genes involved in cell proliferation, survival, and inflammation. Due to the critical role of STAT3 in the pathogenesis of inflammatory diseases and various malignancies, ochromycinone has been investigated for its therapeutic potential in treating psoriasis and certain cancers. Clinical research has included pilot studies evaluating its efficacy as a topical treatment for psoriatic lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ochromycinone.